ReviewFrontiers in endocrinology2022
Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm.Endocrine · 2025Pooled it
- Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives.International journal of molecular sciences · 2024Pooled it
- Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes.Pituitary · 2026Review
- Systemic Molecularly Targeted Therapies for Neoadjuvant and Salvage Craniopharyngioma: A Contemporary Narrative Review.Biomedicines · 2026Review
- Efficacy and safety of BRAF-MEK inhibitors in treatment of Chinese patients with papillary craniopharyngioma: A retrospective cohort study.Molecular therapy. Oncology · 2025Article
- Targeted therapy of papillary craniopharyngioma.Medical oncology (Northwood, London, England) · 2025Review
- Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.Neuro-oncology advances · 2025Article
- Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review.Neurologia medico-chirurgica · 2025Article
- Targeted treatment for craniopharyngioma.Journal of neuro-oncology · 2025Review
- Current clinical trials for craniopharyngiomas: what's on the horizon?Journal of neuro-oncology · 2025Review
- Identification of factors related to functional prognoses in craniopharyngiomas.Journal of neuro-oncology · 2025Article
- Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.Acta neuropathologica communications · 2025Article
- Advances in the Management of Craniopharyngioma: A Narrative Review of Recent Developments and Clinical Strategies.Journal of clinical medicine · 2025Review
- A case-based review of adult-onset craniopharyngioma.Frontiers in endocrinology · 2025Review
- Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.Frontiers in endocrinology · 2025Review
- Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.Journal of endocrinological investigation · 2024Review
- Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review.Cancers · 2024Review
- Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Practical application of precision oncology in adult onset craniopharyngiomas.Frontiers in endocrinology · 2024Review
- Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma.Endocrine oncology (Bristol, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgical and clinical management of craniopharyngiomas is associated with high long-term morbidity especially in the case of hypothalamic involvement. Improvements in knowledge of craniopharyngioma molecular biology may offer the possibility of safe and effective medical neoadjuvant treatments in a subset of patients harboring papillary subtype tumors with a BRAFV600E mutation. Method: We report herein two cases of tubero-infundibular and ventricular Papillary Craniopharyngiomas in which BRAF/MEK inhibitor combined therapy was used as adjuvant (Case 1) or neoadjuvant (Case 2) treatment, with a 90% reduction in tumor volume observed after only 5 months. In Case 2 the only surgical procedure used was a minimal invasive biopsy by the trans-ventricular neuroendoscopic approach. As a consequence, targeted therapy was administered in purely neoadjuvant fashion. After shrinkage of the tumor, both patients underwent fractionated radiotherapy on the small tumor remnant to achieve long-term tumor control. A review of a previously reported case has also been performed. Result: This approach led to tumor control with minimal long-term morbidity in both cases. No side effects or complications were reported after medical treatment and adjuvant radiotherapy. Conclusion: Our experience and a review of the literature argue for a change in the current treatment paradigm for Craniopharyngiomas (CPs). In giant and invasive tumors, confirmation of BRAFV600E mutated PCPs by biopsy and BRAF/MEK inhibitor therapy before proposing other treatments may be useful to improve long term outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.